Novartis AG (SWX:NOVN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 230.47B +23.5% |
| Revenue (ttm) | 45.38B +6.3% |
| Net Income | 10.86B +5.2% |
| EPS | 5.60 +9.5% |
| Shares Out | 1.83B |
| PE Ratio | 22.48 |
| Forward PE | 17.38 |
| Dividend | 3.70 (2.92%) |
| Ex-Dividend Date | Mar 10, 2026 |
| Volume | 2,243,413 |
| Open | 126.32 |
| Previous Close | 126.80 |
| Day's Range | 125.26 - 126.52 |
| 52-Week Range | 91.20 - 131.00 |
| Beta | 0.50 |
| Analysts | Hold |
| Price Target | 123.91 (-1.58%) |
| Earnings Date | Jul 21, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for NOVN stock is "Hold." The 12-month stock price target is CHF 123.91, which is a decrease of -1.58% from the latest price.
News
The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
Markets are being tested again. The AI trade has spent the past several weeks under real pressure, with memory, semiconductor, and neocloud names selling off hard after an extraordinary first half.
Novartis Buys Myricx Bio in Up to $1.5 Billion Cancer Drug Deal
Novartis Buys Myricx Bio in Up to $1.5 Billion Cancer Drug Deal
Novartis Acquires Myricx Bio for Up to $1.5 Billion
Novartis Acquires Myricx Bio for Up to $1.5 Billion
Novartis (NVS) to Acquire Myricx Bio for Up to $1.5 Billion
Novartis (NVS) to Acquire Myricx Bio for Up to $1.5 Billion
Novartis (NVS) Expands Oncology Pipeline with Myricx Bio Acquisition
Novartis (NVS) Expands Oncology Pipeline with Myricx Bio Acquisition
Novartis to Acquire Myricx Bio for $1.5B to Boost Cancer Drugs; NVS Stock Falls
Swiss pharmaceutical company Novartis ($NVS) acquired UK-based private biotech firm Myricx Bio for $1.5 billion, including $1.1 billion upfront in cash. The deal brings together Novartis’ cancer drug ...
Novartis agrees to acquire Myricx Bio for up to $1.5B
Novartis (NVS) announced that it has entered into an agreement to acquire Myricx Bio, a privately held UK-based biotechnology company developing a new class of antibody-drug conjugates, using N-myrist...
Novartis to acquire Myricx Bio for $1.1B upfront
Myricx Bio, a UK-headquartered biotech company, announced that it has reached agreement to be acquired by Novartis (NVS) for up to $1.5B including $1.1B cash upfront plus potential milestone payments.
Novartis Buys Myricx Bio in $1.5 Billion Deal
Novartis Buys Myricx Bio in $1.5 Billion Deal
Novartis (NVS) to Acquire Myricx Bio for Up to $1.5B to Enhance Oncology Pipeline
Novartis (NVS) to Acquire Myricx Bio for Up to $1.5B to Enhance Oncology Pipeline
Novartis To Acquire Myricx Bio In Deal Valued Up To $1.5 Bln, Expand Oncology Pipeline
(RTTNews) - Novartis AG (NVS) announced on Monday its agreement to acquire Myricx Bio, a UK-based biotechnology company developing a new class of antibody-drug conjugates, or ADCs, for up to $1.5 bill...
Novartis to Buy Myricx Bio for Up to $1.5 Billion
The deal for the privately held U.K.-based biotechnology firm will help bolster Novartis's oncology capabilities.
Aussie super funds hit the jackpot in $2b biotech deal
Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological missiles”, to Swiss giant Novartis.
Novartis to acquire UK-based Myricx Bio for up to $1.5 billion
Swiss drugmaker Novartis said on Monday it had agreed to pay up to $1.5 billion for U.K.-based biotechnology firm Myricx Bio in a deal expected to close in the second half of 2026.
Novartis AG (NVS) Stock Up 3.7% but GF Value Says Overvalued -- GF Score: 82/100
Novartis AG (NVS) Stock Up 3.7% but GF Value Says Overvalued -- GF Score: 82/100
Novartis (NVS) Gains EU Approval for Itvisma Gene Therapy for SMA
Novartis (NVS) Gains EU Approval for Itvisma Gene Therapy for SMA
Novartis (NVS) Secures Approval for Itvisma in SMA Treatment
Novartis (NVS) Secures Approval for Itvisma in SMA Treatment
Novartis receives EC approval for Itvisma for spinal muscular atrophy
Novartis (NVS) announced that the European Commission, EC, has approved Itvisma for the treatment of children two years and older, teens and adults living with 5q spinal muscular atrophy, SMA,…
Novartis Granted EC Approval For Itvisma In Treating Spinal Muscular Atrophy
(RTTNews) - Novartis AG (NVS), a pharmaceutical company, on Thursday reported receiving approval from the European Commission (EC) for Itvisma, a gene therapy developed for the treatment of children, ...
Novartis Announces Approval Of Itvisma In Europe For Spinal Muscular Atrophy
(RTTNews) - Novartis (NVS, NOVN.SW) announced that the European Commission has approved Itvisma or onasemnogene abeparvovec for the treatment of children two years and older, teens and adults living w...
3 European Stocks to Carry Investors Through the Back Half of 2026
The first half of the year is over, and it may surprise some investors that European stocks are nearly at parity with U.S. stocks. The tale of the tape as of June 30 tells the story:
The Zacks Analyst Blog Highlights JPMorgan, Novartis, Qualcomm, Genie and ImmuCell
Micron surged after strong Q3 results, robust AI-driven memory demand and a bullish Q4 outlook. See which ETFs have notable exposure.
Top Stock Reports for JPMorgan, Novartis & Qualcomm
JPMorgan, Novartis and Qualcomm headline today's top stock reports, highlighting growth drivers, competitive pressures and key catalysts ahead.
Novartis Eyes $5 Billion Pluvicto Opportunity
Novartis Eyes $5 Billion Pluvicto Opportunity
Novartis Targets Hard-to-Treat Cancers
Novartis Targets Hard-to-Treat Cancers